CA
NAUT icon

Clearstead Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Clearstead Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Sell
892,787
-1,436,997
-62% -$3.79M 0.02% 421
2026
Q1 		$9.04M Buy
+2,329,784
New +$5.72M 0.08% 174

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Clearstead Advisors's NAUT Position: Q2 2026 in Review

Clearstead Advisors reduced its Nautilus Biotechnolgy (NAUT) stake by 62% in Q2 2026, selling an estimated $3.79M and leaving 892,787 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #421.

Clearstead Advisors first reported a position in NAUT in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.04M in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Clearstead Advisors held 892,787 shares of Nautilus Biotechnolgy worth $1.67M as of Q2 2026.
  • Clearstead Advisors sold 1,436,997 Nautilus Biotechnolgy shares in Q2 2026, an estimated $3.79M.
  • Nautilus Biotechnolgy made up 0.02% of Clearstead Advisors's portfolio in Q2 2026, its #421 holding.
  • Clearstead Advisors first reported a position in Nautilus Biotechnolgy in Q1 2026 and has held it in 2 quarters since.
  • Clearstead Advisors's Nautilus Biotechnolgy position peaked at $9.04M in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.